All Data
Lead Product(s): Ridinilazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 02, 2020
Details:
Funds support continued patient enrolment into the Ri-CoDIFy Phase 3 clinical trial program of ridinilazole for the treatment of Clostridium difficile infection; launch of Ridinilazole and Development of early-stage research projects using the Company’s Discuva Platform.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Delafloxacin
Therapeutic Area: Infections and Infectious Diseases Product Name: Quofenix
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
Details:
Menarini Ricerche has published four abstracts presenting the latest findings related to its meropenem/vaborbactam (Vaborem™) and delafloxacin (Quofenix™) clinical studies, confirming Menarini’s commitment to fighting life-threatening bacterial infections.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
